4-{6-[4-(piperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}quinoline

• ChemBase ID: 73113
• Molecular Formular: C25H22N6
• Molecular Mass: 406.48238
• Monoisotopic Mass: 406.19059473
• SMILES: c1(ccc(cc1)c1cnc2n(c1)ncc2c1ccnc2c1cccc2)N1CCNCC1
• Canonical SMILES: N1CCN(CC1)c1ccc(cc1)c1cnc2n(c1)ncc2c1ccnc2c1cccc2
• InChI: InChI=1S/C25H22N6/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2
• InChIKey: CDOVNWNANFFLFJ-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 4-{6-[4-(piperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}quinoline
• IUPAC Traditional name: 4-{6-[4-(piperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}quinoline
• Synonyms: LDN 193189; LDN193189

Database IDs

• CAS Number: 1062368-24-4
• PubChem SID: 162038033
• PubChem CID: 25195294

CALCULATED PROPERTIES

• H Acceptors: 5
• H Donor: 1
• LogD (pH = 5.5): 0.67203116
• LogD (pH = 7.4): 2.1977062
• Log P: 3.6771934
• Molar Refractivity: 133.1513 cm^3
• Polarizability: 50.401436 Å^3
• Polar Surface Area: 58.35 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: true

PROPERTIES

Safety Information

• Storage Condition: -20°C

Pharmacology Properties

• Target: ALK

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S2618

Research Area

• Description: Cancer

Biological Activity

• Description: LDN193189 is a selective inhibitor of ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively.
• Targets: ALK2; ALK3
• IC50: 5 nM ^[1]; 30 nM ^[1]
• In Vitro: LDN193189 potently inhibits BMP4-mediated Smad1, Smad5 and Smad8 activation with IC50 of 5 nM, and efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively. Furthermore, LDN193189 also shows the inhibitory effect on the transcriptional activity induced by either constitutively active ALK2^R206H or ALK2^Q207D mutant proteins. ^[1] A recent study shows that LDN-193189 blocks the production of reactive oxygen species induced by oxidized LDL during atherogenesis in human aortic endothelial cells. ^[4]
• In Vivo: In conditional caALK2-transgenic mice with Ad.Cre on on postnatal day 7 (P7), LDN-193189 (3 mg/kg i.p) leads to mild calcifications surrounding the left tibia and fibula first visible at P13, and prevents radiographic lesions at P15 without causing weight loss or growth retardation, spontaneous fractures, decreased bone density or behavioral abnormalities. ^[1] LDN193189 dorsalizes zebrafish embryos by inhibiting signaling pathways induced by bone morphogenetic protein (BMP)6 without effect on vascular development. ^[2] In PCa-118b tumor-bearing mice, LDN-193189 treatment attenuates tumor growth and reduces bone formation in the tumors. ^[3] In LDL receptor-deficient (LDLR-/-) mice, LDN-193189 potently inhibits development of atheroma. Moreover, LDN-193189 also exhibits the inhibitory effects on associated vascular inflammation, osteogenic activity, and calcification. ^[4]

Protocol

• Protocol: Kinase Assay ^[1]
• Alkaline phosphatase activity: C2C12 cells are seeded into 96-well plates at 2,000 cells per well in DMEM supplemented with 2% FBS. The wells are treated in quadruplicate with BMP ligands and LDN-193189 or vehicle. The cells are collected after 6 days in culture in 50 μL Tris-buffered saline and 1% Triton X-100. The lysates are added to p-nitro-phenylphosphate reagent in 96-well plates for 1 hours and then evaluated alkaline phosphatase activity (absorbance at 405 nm). Cell viability and quantity are measured by Cell Titer Aqueous One (absorbance at 490 nm), using replicate wells treated identically to those used for alkaline phosphatase measurements.
• Protocol: Animal Study ^[1]
• Animal Models: Ad.Cre on P7 is injected into conditional caALK2–transgenic and wild-type mice.
• Formulation: LDN193189 is dissolved in DMSO and then diluted in water.
• Doses: ≤3 mg/kg
• Administration: Administered via i.p.

References

• References: [1] Yu PB, et al. Nat Med, 2008, 14(12), 1363-1369.
• References: [2] Cannon JE, et al. Br J Pharmacol, 2010, 161(1), 140-149.
• References: [3] Lee YC, et al. Cancer Res, 2011, 71(15), 5194-5203.
• References: [4] Derwall M, et al. Arterioscler Thromb Vasc Biol, 2012, 32(3), 613-622.

REFERENCES

• Yu PB, et al. Nat Med, 2008, 14(12), 1363-1369.
• Cannon JE, et al. Br J Pharmacol, 2010, 161(1), 140-149.
• Lee YC, et al. Cancer Res, 2011, 71(15), 5194-5203.
• Derwall M, et al. Arterioscler Thromb Vasc Biol, 2012, 32(3), 613-622.